Figure 2.

Combined cytotoxic effects of cisplatin plus etoposide (PE) or cisplatin plus irinotecan (PI) with selective UCHL1 inhibitors and the inhibitors alone on small cell lung cancer (SCLC) cells using the MTS assay. A, The combination of PE or PI and the selective UCHL1 inhibitors WP1130 and LDN57444 increased the therapeutic effects in H82 and H526 cells but not in non–small cell lung cancer (NSCLC) lines. LDN57444 or WP1130 alone had an effect compared with a PE or PI regimen on H82 cells. B, Treatment responses in SCLC and NSCLC were summarized with the IC₅₀